...A. 2024 also saw continued growth in our core businesses, sample management solutions and multiomic, where we continue to play an integral role in helping our customers bring impactful breakthroughs through market fast to market faster. B. At the same time, we also announced the planned divestiture of our, the Medical business which will enable us to streamline our portfolio and focus on driving more growth and profitability. C. From a balance sheet perspective, we completed our $1.5 billion share repurchase authorization, returning significant capital to our shareholders, while maintaining a healthy cash balance of over $500 million to enable us to continue to invest in our future growth. D. In November, we added three outstanding directors and Will Cornog, Quentin Koffey and Alan Malus. E. Mr Secretary thus far we have 43,490,462 shares of common stock present in person or by proxy, out of the 45,691,888 shares that were outstanding and entitled to vote....
